An Indiana biotech pioneer developing novel therapeutics for untreatable diseases by targeting multiprotein complexes with proprietary small molecule modulators that restore cellular homeostasis and combat infectious diseases.
Modulant's proprietary platform targets aberrant multiprotein complexes with small molecule allosteric modulators that restore cellular homeostasis, prevent pathogen subversion of host immunity, and address chronic diseases by reestablishing normal protein assembly dynamics.
Modulant's pipeline targets high-impact veterinary diseases through proprietary allosteric modulation technology, focusing on feline infectious diseases, canine cancer, and swine respiratory illness.
Modulant pioneers a revolutionary antiviral approach by uniquely targeting host cellular functions rather than viruses directly. This proprietary mechanism represents a significant market advancement with no competing compounds in development.